Martoni A, Pacciarini M A, Pannuti F
Eur J Cancer Clin Oncol. 1985 Jul;21(7):803-6. doi: 10.1016/0277-5379(85)90218-4.
The new anthracycline-analogue 4-demethoxydaunorubicin (4-DMDR) was administered orally at the dose of 15 mg/m2 daily for three consecutive days and repeated every 21-28 days on 29 patients with advanced pretreated breast cancer. A partial remission was observed in 7/25 evaluable patients (28%) for a median duration of 7 months. Side-effects include leukopenia in 93% of the patients (less than 1000 WBC/mm3 in 7%), nausea in 41%, mild vomiting in 17%, diarrhea in 10% and alopecia in 10% of the patients. No definitive conclusion is possible regarding cardiotoxicity. Only mild changes in ECG were observed in two patients. This study shows that 4-DMDR administered orally is well tolerated in the majority of patients and has antitumor activity in advanced breast cancer.
对29例晚期经预处理的乳腺癌患者，口服给予新的蒽环类类似物4-去甲氧基柔红霉素（4-DMDR），剂量为每日15mg/m²，连续给药3天，每21 - 28天重复一次。在25例可评估患者中有7例（28%）出现部分缓解，中位缓解持续时间为7个月。副作用包括93%的患者出现白细胞减少（7%的患者白细胞计数低于1000/mm³），41%的患者出现恶心，17%的患者出现轻度呕吐，10%的患者出现腹泻，10%的患者出现脱发。关于心脏毒性无法得出明确结论。仅在2例患者中观察到心电图有轻微变化。本研究表明，口服4-DMDR在大多数患者中耐受性良好，对晚期乳腺癌具有抗肿瘤活性。
